Source: International Congress 2019 – Drug-resistant tuberculosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
A. Skrahina (Minsk, Belarus), H. Hurevich (Minsk, Belarus), S. Setkina (Minsk, Belarus), V. Grankov (Minsk, Belarus), V. Solodovnikova (Minsk, Belarus), D. Viatushka (Minsk, Belarus), V. Kralko (Minsk, Belarus), D. Klimuk (Minsk, Belarus), M. Dara (Copenhagen, Denmark). Bedaquiline containing regimens for the treatment of multi- and extensively drug-resistant tuberculosis at the programmatic level in Belarus. Prospective cohort study.. 2136

Member's Comments

No comment yet.

Related content which might interest you: Multicentre randomised clinic study of new standard chemotherapy regimen for new cases patients of pulmonary tuberculosis executed in Russia regions with high level of multiple drug resistance (MDR) Source: Annual Congress 2009 - Tuberculosis control Year: 2009 Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea Source: Eur Respir J, 51 (3) 1702467; 10.1183/13993003.02467-2017 Year: 2018 Concurrent use of bedaquiline and delamanid for the treatment of fluoroquinolone-resistant multidrug-resistant tuberculosis: a nationwide cohort study in South Korea Source: Eur Respir J, 57 (3) 2003026; 10.1183/13993003.03026-2020 Year: 2021 Clofazimine for the treatment of multidrug-resistant tuberculosis: Prospective, multicenter, randomized controlled study in China Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 The treatment outcomes of isoniazid resistant tuberculosis: Multicenter and retrospective study in South Korea Source: Annual Congress 2010 - Emerging drug resistance in tuberculosis Year: 2010 Guidelines of tuberculosis preventive therapy for HIV-infected persons: a prospective, multicentre study Source: Eur Respir J 2001; 18: 369-375 Year: 2001 Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens Source: Eur Respir J, 50 (5) 1701105; 10.1183/13993003.01105-2017 Year: 2017 Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study Source: Eur Respir J, 49 (5) 1700387; 10.1183/13993003.00387-2017 Year: 2017 Evaluation of optimal regimens for treatment of rifampicin resistant-tuberculosis: Multicenter, randomized controlled study in China Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Treatment of multidrug-resistant tuberculosis (MDR-TB) with modified shorter all-oral treatment regimen (mSTR) under operational research conditions in Belarus Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 Tuberculosis in HIV-infected persons in the context of wide availability of highly active antiretroviral therapy Source: Eur Respir J 2004; 24: 11-17 Year: 2004 Long-term safety and tolerability of delamanid-containing regimens in multidrug-resistant and extensively drug-resistant tuberculosis patients in a specialised treatment centre in Berlin, Germany Source: Eur Respir J, 56 (6) 2000009; 10.1183/13993003.00009-2020 Year: 2020 Multidrug-resistance tuberculosis and HIV-infected patients, the effectiveness of the treatment in Ukraine Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010 Time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis: a prospective cohort study from urban China Source: Eur Respir J , 49 (3) 1601558; DOI: 10.1183/13993003.01558-2016 Year: 2017 Effectiveness of mandatory treatment for tuberculosis - An observational registry study Source: Annual Congress 2013 –Epidemiological and public health features of tuberculosis Year: 2013 Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China Source: Eur Respir J, 57 (3) 2003463; 10.1183/13993003.03463-2020 Year: 2021 The use of totally implantable central venous access ports for the treatment of multidrug-resistant tuberculosis (MDR-TB) at the programmatic level. Prospective cohort study Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019 Prospective study of mycobacterium tuberculosis drug resistance in Tunisia Source: Eur Respir J 2004; 24: Suppl. 48, 658s Year: 2004 A multicentric cohort analysis of culture conversion and reversion in multidrug resistant tuberculosis (MDRTB) patients Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013 First countrywide observational study of acquired drug resistance among TB cases in Ukraine Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020